Founded in 2012, Cureab conducts research in inflammation and oncology, with a specific focus on lung, liver, and colorectal cancer. They develop antibodies for cancer therapy, from target identification to clinical testing. Currently, two monoclonal antibodies are in late-stage pre-clinical development. Cureab actively seeks partnerships with academia and industry to further their research and development efforts.